Across the United States, a quiet but consequential policy shift is underway: instead of banning kratom outright, a growing number of states are choosing to regulate it, building consumer-protection frameworks around an herb that remains federally legal yet highly controversial.
At the heart of this shift is the Kratom Consumer Protection Act (KCPA), a model law that has been introduced in legislatures around the country and, in various forms, adopted in states from Utah and Nevada to Florida, Texas, Virginia, Oregon and Colorado, each requiring testing, labeling and age limits rather than criminalizing possession or use of kratom products. Industry and advocacy groups such as the American Kratom Association closely track these measures, arguing that a regulated market is far safer for consumers than an unregulated gray area or an outright ban.
According to a 2024 policy review by the nonpartisan Legislative Analysis and Public Policy Association, at least 16 states now regulate the manufacture, sale or distribution of kratom products, with ten of those states, including Arizona, Colorado, Georgia, Nevada, Oklahoma, Tennessee, Texas, Utah, Virginia and West Virginia, imposing specific labeling requirements to disclose ingredients, alkaloid content and warning statements.
Separate industry tallies put the number of states that have adopted some form of KCPA-style legislation even higher, highlighting Oregon, Colorado, Utah, Georgia, Arizona, Nevada, Missouri, West Virginia, Virginia, Texas, Florida, Kentucky and Maryland among those that have embraced consumer-protection models that focus on testing, age restrictions and product standards instead of prohibitions. A recent overview of KCPA adoption summarized these states as the leading edge of a national trend toward formal kratom regulation and away from blanket bans.
In contrast, only a small group of states have moved to ban kratom completely. Public health summaries and legal guides consistently list Alabama, Arkansas, Indiana, Rhode Island, Vermont and Wisconsin among the states where kratom is illegal to buy, sell, possess or use, with Louisiana scheduled to implement a statewide ban in 2025 after earlier local-level restrictions. For lawmakers in those jurisdictions, concerns about addiction, contamination and limited safety data have outweighed calls for a regulated marketplace.
The U.S. Food and Drug Administration has taken a distinctly skeptical stance, warning consumers not to use kratom because of potential safety risks and its unapproved status as a drug, while also documenting reports of contamination and adulteration in certain kratom-containing products. In public advisories, the agency has stressed that some kratom products have tested positive for heavy metals and pathogens like salmonella and that kratom has been linked, often in combination with other substances, to a number of serious adverse events and deaths, according to its kratom information page.
That federal skepticism, combined with a lack of approved medical uses, has prompted calls from some public health officials and medical organizations for stricter national controls, but efforts to place kratom’s primary alkaloids, mitragynine and 7-hydroxymitragynine, on the federal list of controlled substances have not succeeded. The Drug Enforcement Administration considered emergency scheduling in 2016 but backed away after substantial public and congressional pushback, leaving the regulatory field to individual states and localities.
In that vacuum, the KCPA has become the policy instrument of choice for states trying to thread a narrow needle between public safety and consumer access. Typical KCPA provisions bar the sale of adulterated or contaminated kratom products, require manufacturing and testing standards, mandate clear labeling, and impose minimum-age requirements that often set the bar at 18 or 21 years old. Utah, which in 2019 became the first state to enact a kratom consumer protection framework, requires registration of kratom products, testing for contaminants, and warning labels under a statute administered by its Department of Agriculture and Food, setting an early template for other states to emulate.
Other jurisdictions have followed with their own variations. Nevada passed a KCPA in 2019 that makes the sale of contaminated or adulterated kratom products a punishable offense and restricts purchases to adults, while Texas approved a kratom consumer protection law in 2023 that similarly focuses on age restrictions, labeling and prohibitions on potentially dangerous additives. Florida lawmakers have advanced their own consumer-protection bill, backed by industry and advocacy groups, to regulate kratom under state law and prevent sales to minors.
In Virginia and West Virginia, newly enacted kratom laws require detailed product labeling, prohibit sales to underage buyers and give state agencies authority to enforce testing and safety standards. Colorado has moved from a largely unregulated market to a codified framework that includes licensing requirements for kratom manufacturers and distributors, product testing protocols and restrictions on marketing that might appeal to minors, reflecting a broader shift in how the state approaches emerging psychoactive substances.
Oregon has taken a similar approach, tasking its health and agriculture agencies with creating rules under a statewide kratom consumer protection statute that covers testing, labeling and age limits. Legislative drafters there have framed the law as a way to tackle unregulated products and protect consumers while acknowledging that outright prohibition could push kratom into illicit channels where there is even less oversight.
Behind these policy decisions lies a convergence of political, scientific and practical considerations. Many lawmakers point to the reality that kratom is already widely available online and, in many states, on store shelves, even in the absence of clear regulatory standards. Advocates have successfully argued in legislative hearings that trying to ban a substance with millions of users nationwide is both politically fraught and, in the era of e-commerce, difficult to enforce, particularly when neighboring states allow kratom sales.
Supporters of regulation instead of prohibition also highlight the emerging research on kratom’s pharmacology and use patterns. While federal health agencies emphasize reports of toxicity and potential for dependence, several observational studies published in recent years suggest that many people in the U.S. use kratom to self-manage pain, anxiety or symptoms associated with opioid withdrawal, and that a significant number report reduced reliance on prescription or illicit opioids. Those findings, while preliminary and not a substitute for controlled clinical trials, have informed legislative debates in states considering KCPA bills.
For elected officials, the choice has often come down to whether kratom should be managed like a controlled substance, with criminal penalties and prohibition, or like a dietary supplement or other consumer product that requires guardrails but remains legal for adults. The KCPA model situates kratom squarely in the latter category, with state agencies overseeing product standards and enforcement rather than police and prosecutors driving policy through criminal law.
There is also a political calculus. In states where libertarian-leaning or small-government sentiment is strong, proposals to ban kratom outright have repeatedly stalled amid concerns about overreach and the potential impact on individuals who say they rely on the plant for chronic pain or other conditions. In Kentucky, for example, a proposed statewide ban was shelved in favor of exploring consumer-protection measures after testimony from users and advocates, illustrating how personal stories and grassroots lobbying have shaped legislative outcomes.
Industry groups and advocacy organizations have played an organized role as well. The American Kratom Association, which promotes KCPA legislation as a way to “keep kratom legal and safe,” provides legislators with model bills, state-specific data and testimony, while the Global Kratom Coalition’s regulation map offers a visual snapshot of which states have bans, regulations or pending bills, helping lawmakers and the public track the evolving legal landscape.
Those groups argue that regulation addresses many of the concerns raised by the FDA and state health departments by targeting the very issues that have led to adverse events: contamination, adulteration and lack of transparency. By requiring third-party testing, banning synthetic or highly concentrated derivatives, and mandating clear labels with alkaloid content and warnings, KCPA-style laws are designed to prevent the most dangerous products from reaching consumers while preserving access to traditional kratom preparations.
Critics remain unconvinced, warning that even with consumer protections, kratom can carry risks, particularly for individuals with underlying health conditions or those who combine it with other substances. Some public health experts argue that regulating kratom like a supplement may inadvertently normalize its use and make it appear safer than the evidence currently supports, and they call for stronger surveillance, better data collection and more rigorous studies to inform future policy decisions.
On the ground, however, the regulatory approach is reshaping how kratom is sold and marketed in states that have adopted KCPA laws. Retailers in those states must comply with testing and labeling rules, age-verification requirements and, in some cases, licensing or registration processes, while distributors who fail to meet standards can face fines, product seizures or, in more serious cases, criminal charges related to adulteration or misbranding.
For consumers, the patchwork remains complex. A kratom product that is legal and regulated in one state may be illegal just across a border where bans remain in place, creating confusion for users who travel or buy products online. Legal commentators advise consumers to check both state law and local ordinances, noting that some cities and counties have imposed their own restrictions even in states that allow kratom sales, adding yet another layer to the regulatory map.
Even so, the momentum appears to favor regulation over prohibition. Legal analyses published in 2025 note that while the number of states with total bans has remained relatively small, the number of jurisdictions adopting some form of kratom regulation continues to rise, fueled by KCPA campaigns and a growing recognition that leaving a widely used psychoactive product entirely unregulated poses its own public health challenges.
As kratom policy continues to evolve, the central question for state lawmakers is no longer whether the plant should exist within their borders, but under what conditions. For now, the prevailing answer in many capitols is to regulate rather than outlaw, betting that a structured, transparent marketplace with clear rules will better protect the public than pushing kratom into the shadows.